Mean Coronary Cross-Sectional Area as a Measure of Arterial Remodeling Using Noncontrast CT Imaging in Persons With HIV

Ayoda T Werede, James G Terry, Sangeeta Nair, Tecla M Temu, Bryan E Shepherd, Samuel S Bailin, Mona Mashayekhi, Curtis L Gabriel, Morgan Lima, Beverly Owen Woodward, LaToya Hannah, Simon A Mallal, Joshua A Beckman, Jonathan Z Li, Jesse Fajnzylber, David G Harrison, John Jeffrey Carr, John R Koethe, Celestine N Wanjalla, Ayoda T Werede, James G Terry, Sangeeta Nair, Tecla M Temu, Bryan E Shepherd, Samuel S Bailin, Mona Mashayekhi, Curtis L Gabriel, Morgan Lima, Beverly Owen Woodward, LaToya Hannah, Simon A Mallal, Joshua A Beckman, Jonathan Z Li, Jesse Fajnzylber, David G Harrison, John Jeffrey Carr, John R Koethe, Celestine N Wanjalla

Abstract

Background Persons with HIV have a higher prevalence of coronary artery disease compared with their HIV-negative counterparts. Earlier identification of subclinical atherosclerosis may provide a greater opportunity for cardiovascular disease risk reduction. We investigated coronary cross-sectional area (CorCSA) by noncontrasted computed tomography imaging as a noninvasive measure of arterial remodeling among virally suppressed persons with HIV. Methods and Results We assessed 105 persons with HIV with a spectrum of cardiometabolic health. All participants underwent computed tomography imaging to assess the mean corCSA of the proximal left anterior descending artery and 28 participants underwent additional coronary computed tomography angiography. Partial Spearman rank correlations adjusted for cardiovascular disease risk factors were used to assess relationships of corCSA with anthropometric measurements, HIV-related factors, and plasma cytokines. Mean corCSA measured by noncontrast computed tomography and coronary computed tomography angiography were strongly correlated (ρ=0.91, P<0.0001). Higher mean corCSA was present in those with coronary artery calcium (P=0.005) and it correlated with participants' atherosclerotic cardiovascular disease risk score (ρ=0.35, P=0.01). After adjusting for established cardiovascular disease risk factors, we observed an inverse relationship between corCSA and CD4+ T-cell count (ρ=-0.2, P=0.047). Removal of age from the model strengthened the relationships between corCSA and antiretroviral therapy duration (from ρ=0.19, P=0.08 to ρ=0.3, P=0.01). CorCSA was also inversely correlated with plasma IL-10 (ρ=-0.25, P=0.03) but had no relationship with IL-6 (ρ=0.11, P=0.4) or IL-1β (ρ=0.08, P=0.5). Conclusions Positive coronary arterial remodeling, an imaging marker of subclinical atherosclerosis, is associated with a lower CD4 T-cell count, lower circulating IL-10, and possibly a longer antiretroviral therapy duration in persons with HIV. Registration Clinicaltrials.gov; Unique identifier: NCT04451980.

Keywords: cardiovascular diseases; coronary arterial calcium; coronary artery disease; cross‐sectional area; glycated hemoglobin A; interleukin‐10; interleukin‐6.

Figures

Figure 1. Mean corCSA is higher with…
Figure 1. Mean corCSA is higher with coronary calcium and correlated with ASCVD risk.
Representative computed tomography image (CT) demonstrating the technique for measuring coronary cross‐sectional area (corCSA) of the proximal left anterior descending coronary artery (LAD) using previously published methods. The proximal 1.0 cm of the LAD was identified, at 3 equidistant points as labeled a, b, and c. The corCSA includes the area of the wall of the vessel as well as the lumen. Mean corCSA is the average of all 3 areas (A). Notched box plots showing mean corCSA by diabetes status (B) and by quantifiable calcium on CT imaging (C). Box plots showing current atherosclerotic cardiovascular disease (ASCVD) risk score in persons with HIV (PWH) with and without coronary artery calcium (CAC) (D) and correlation between ASCVD risk score and corCSA (E). Correlation plot of corCSA measurements obtained by noncontrast CT and coronary computed tomography angiography imaging (n=28). Analyses were performed using Kruskal–Wallis test (B), Mann–Whitney U tests (C and D), and Spearman rank correlation (E and F).
Figure 2. Mean coronary cross‐sectional area (corCSA)…
Figure 2. Mean coronary cross‐sectional area (corCSA) correlation with cardiovascular disease risk factors.
Unadjusted Spearman rank correlation plots of mean corCSA and weight (A), height (B), body mass index (C), waist circumference (D), age (E), low‐density lipoprotein cholesterol (LDL) (F), high‐density lipoprotein cholesterol (HDL) (G), hemoglobin A1c (H), triglycerides (I), and creatinine (J). Statistical analyses were performed using Spearman rank correlation.
Figure 3. Mean coronary cross‐sectional area (corCSA)…
Figure 3. Mean coronary cross‐sectional area (corCSA) correlates with age and waist circumference in adjusted models.
Partial Spearman rank correlation analysis adjusted for hypertension (HTN), smoker status, sex, statin use, and coronary artery calcium (CAC) prevalence in all persons with HIV (PWH) (n=105) (A), PWH without diabetes (n=38) (B), and PWH who were prediabetic/diabetic (n=68) (C). HDL indicates high‐density lipoprotein cholesterol; HsCRP, high‐sensitivity C‐reactive protein; and LDL, low‐density lipoprotein cholesterol.
Figure 4. Mean coronary cross‐sectional area (corCSA)…
Figure 4. Mean coronary cross‐sectional area (corCSA) positively correlates with duration of antiretroviral therapy (ART), cell‐associated HIV RNA/DNA, and negatively with CD4 T cell count.
Unadjusted correlation plots of mean corCSA and duration of ART in all persons with HIV (PWH) by diabetes status (A) and sex (B). Similar correlation plot of mean corCSA and HIV age (a calculation of the duration of ART divided by age at study enrollment) stratified by metabolic status (C) and sex (D). Mean corCSA was also measured against CD4 T‐cell count at the start of therapy (E), CD4 at study enrollment (F), cell‐associated HIV RNA (G), and cell‐associated HIV DNA (H). Spearman rank test was used for statistical analysis. Note that the correlations are rank‐based whereas the slopes are based on the original data, and therefore, they may not always be in the same direction (eg, Spearman's correlation=−0.016 for those who were nondiabetic in (F), but slightly positive slope with Pearson's correlation=0.17, P=0.33).
Figure 5. Mean coronary cross‐sectional area (corCSA)…
Figure 5. Mean coronary cross‐sectional area (corCSA) is correlated with antiretroviral therapy (ART) duration and the current CD4 T‐cell count.
Partial Spearman correlation analysis adjusted for cardiovascular disease risk factors (A), and with age removed from the model (B). CAC indicates coronary artery calcium; CVD, cardiovascular disease; HbA1c, hemoglobin A1c; HTN, hypertension; and PWH, persons with HIV.
Figure 6. Mean coronary cross‐sectional area (corCSA)…
Figure 6. Mean coronary cross‐sectional area (corCSA) correlation with HIV risk factors differs by diabetes among all PWH.
Partial Spearman correlation analysis adjusted for HbA1c, sex, and waist circumference in PWH without diabetes with (A) and without age (B). A similar analysis in PWH with prediabetes and diabetes adjusted for HbA1c, waist circumference, HTN, sex, and CAC prevalence with (C) and without age (D). ART indicates antiretroviral therapy; CAC, coronary artery calcium; HbA1c, hemoglobin A1c; HTN, hypertension; and PWH, persons with HIV.
Figure 7. Mean coronary cross‐sectional area (corCSA)…
Figure 7. Mean coronary cross‐sectional area (corCSA) is negatively associated with plasma IL‐10.
Box plots showing plasma cytokines from nondiabetic, prediabetic combined with diabetic PWH (A). Forest plot showing the adjusted (age, sex, HbA1c, HTN, waist circumference, smoker status, statin use, and the presence of CAC) correlation between corCSA and cytokines in all PWH (B), PWH without diabetes adjusted for age, HbA1c, sex, and waist circumference (C), and PWH who were prediabetic/diabetic adjusted for age, HbA1c, sex, waist circumference, and the presence of CAC (D). Mann–Whitney test and partial Spearman rank test were used for statistical analysis. CAC indicates coronary artery calcium; HbA1c, hemoglobin A1c; HTN, hypertension; and PWH, persons with HIV.

References

    1. Alonso A, Barnes AE, Guest JL, Shah A, Shao IY, Marconi V. HIV infection and incidence of cardiovascular diseases: an analysis of a large healthcare database. J Am Heart Assoc. 2019;8:e012241. doi: 10.1161/JAHA.119.012241
    1. Feinstein MJ, Bahiru E, Achenbach C, Longenecker CT, Hsue P, So‐Armah K, Freiberg MS, Lloyd‐Jones DM. Patterns of cardiovascular mortality for HIV‐infected adults in the United States: 1999 to 2013. Am J Cardiol. 2016;117:214–220. doi: 10.1016/j.amjcard.2015.10.030
    1. Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, Longenecker CT, Strachan F, Bagchi S, Whiteley W, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation. 2018;138:1100–1112. doi: 10.1161/CIRCULATIONAHA.117.033369
    1. Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha‐Filho JA, Nasir K, Grinspoon SK. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV‐infected men. AIDS. 2010;24:243–253. doi: 10.1097/QAD.0b013e328333ea9e
    1. Post WS, Budoff M, Kingsley L, Palella FJ, Witt MD, Li X, George RT, Brown TT, Jacobson LP. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med. 2014;160:458–467. doi: 10.7326/M13-1754
    1. Soares C, Samara A, Yuyun MF, Echouffo‐Tcheugui JB, Masri A, Morrison AR, Lin N, Wu WC, Erqou S. Coronary artery calcification and plaque characteristics in people living with HIV: a systematic review and meta‐analysis. J Am Heart Assoc. 2021;10:e019291. doi: 10.1161/JAHA.120.019291
    1. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, Butt AA, Bidwell Goetz M, Leaf D, Oursler KA, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614–622. doi: 10.1001/jamainternmed.2013.3728
    1. Carr JJ, Jr Jacobs DR, Terry JG, Shay CM, Sidney S, Liu K, Schreiner PJ, Lewis CE, Shikany JM, Reis JP, Goff DC Jr. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391–399. doi: 10.1001/jamacardio.2016.5493
    1. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd‐Jones D, McEvoy JW, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American Heart Association/American College of Cardiology Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596–e646. doi: 10.1161/CIR.0000000000000678
    1. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklo M, Bluemke DA, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358:1336–1345. doi: 10.1056/NEJMoa072100
    1. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210–215. doi: 10.1001/jama.291.2.210
    1. Terry JG, Carr JJ, Tang R, Evans GW, Kouba EO, Shi R, Cook DR, Vieira JL, Espeland MA, Mercuri MF, et al. Coronary artery calcium outperforms carotid artery intima‐media thickness as a noninvasive index of prevalent coronary artery stenosis. Arterioscler Thromb Vasc Biol. 2005;25:1723–1728. doi: 10.1161/01.ATV.0000173418.42264.19
    1. Guaraldi G, Zona S, Alexopoulos N, Orlando G, Carli F, Ligabue G, Fiocchi F, Lattanzi A, Rossi R, Modena MG, et al. Coronary aging in HIV‐infected patients. Clin Infect Dis. 2009;49:1756–1762. doi: 10.1086/648080
    1. Kingsley LA, Cuervo‐Rojas J, Muñoz A, Palella FJ, Post W, Witt MD, Budoff M, Kuller L. Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: multicenter AIDS cohort study. AIDS. 2008;22:1589–1599. doi: 10.1097/QAD.0b013e328306a6c5
    1. Mangili A, Gerrior J, Tang AM, O'Leary DH, Polak JK, Schaefer EJ, Gorbach SL, Wanke CA. Risk of cardiovascular disease in a cohort of HIV‐infected adults: a study using carotid intima‐media thickness and coronary artery calcium score. Clin Infect Dis. 2006;43:1482–1489. doi: 10.1086/509575
    1. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron‐beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation. 1995;92:2157–2162. doi: 10.1161/01.cir.92.8.2157
    1. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371–1375. doi: 10.1056/NEJM198705283162204
    1. Schoenhagen P, Nissen SE, Tuzcu EM. Coronary arterial remodeling: from bench to bedside. Curr Atheroscler Rep. 2003;5:150–154. doi: 10.1007/s11883-003-0088-9
    1. Miller PE, Haberlen SA, Metkus T, Rezaeian P, Palella F, Kingsley LA, Witt MD, George RT, Jacobson LP, Brown TT, et al. HIV and coronary arterial remodeling from the Multicenter AIDS Cohort Study (MACS). Atherosclerosis. 2015;241:716–722. doi: 10.1016/j.atherosclerosis.2015.06.022
    1. Zanni MV, Abbara S, Lo J, Wai B, Hark D, Marmarelis E, Grinspoon SK. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV‐infected men. AIDS. 2013;27:1263–1272. doi: 10.1097/QAD.0b013e32835eca9b
    1. Papayannis A, Duprez D, Ge Y, Terry J, Kabagambe E, Lloyd‐Jones D, Lima J, Venkatesh BA, Kishi S, Carr J, et al. Coronary artery structural remodeling by computed tomography and echocardiographic left ventricular mass changes over the next 5 years: the coronary artery risk development in young adults (cardia) study. J Am Coll Cardiol. 2017;69:1604. doi: 10.1016/S0735-1097(17)34993-8
    1. ACC . American College of Cardiology. ASCVD estimator plus (). . 2022.
    1. Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Lederman MM, Para M, Gandhi RT. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS. 2016;30:343–353. doi: 10.1097/QAD.0000000000000953
    1. Ledderose C, Heyn J, Limbeck E, Kreth S. Selection of reliable reference genes for quantitative real‐time PCR in human T cells and neutrophils. BMC Res Notes. 2011;4:427. doi: 10.1186/1756-0500-4-427
    1. Malnati MS, Scarlatti G, Gatto F, Salvatori F, Cassina G, Rutigliano T, Volpi R, Lusso P. A universal real‐time PCR assay for the quantification of group‐M HIV‐1 proviral load. Nat Protoc. 2008;3:1240–1248. doi: 10.1038/nprot.2008.108
    1. Carr JJ, Ge Y, Kabagambe EK, Terry JG, Lloyd‐Jones D, Papayannis A, Duprez DA, Rana JS, Sidney S, Jacobs DR. Coronary artery structural remodeling by computed tomography and cardiovascular disease; the coronary artery risk development in young adults. Circulation. 2017;135(Suppl 1):AP375. doi: 10.1161/circ.135.suppl_1.p375
    1. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827–832. doi: 10.1016/0735-1097(90)90282-t
    1. Wanjalla CN, Mashayekhi M, Bailin S, Gabriel CL, Meenderink LM, Temu T, Fuller DT, Guo L, Kawai K, Virmani R, et al. Anticytomegalovirus CD4+ T cells are associated with subclinical atherosclerosis in persons with HIV. Arterioscler Thromb Vasc Biol. 2021;41(4):1459–1473. doi: 10.1161/ATVBAHA.120.315786
    1. Liu Q, Li C, Wanga V, Shepherd BE. Covariate‐adjusted Spearman's rank correlation with probability‐scale residuals. Biometrics. 2018;74:595–605. doi: 10.1111/biom.12812
    1. Hsue PY, Waters DD. HIV infection and coronary heart disease: mechanisms and management. Nat Rev Cardiol. 2019;16:745–759. doi: 10.1038/s41569-019-0219-9
    1. Moore KW, de Waal MR, Coffman RL, O'Garra A. Interleukin‐10 and the interleukin‐10 receptor. Annu Rev Immunol. 2001;19:683–765. doi: 10.1146/annurev.immunol.19.1.683
    1. Lakoski SG, Liu Y, Brosnihan KB, Herrington DM. Interleukin‐10 concentration and coronary heart disease (CHD) event risk in the estrogen replacement and atherosclerosis (ERA) study. Atherosclerosis. 2008;197:443–447. doi: 10.1016/j.atherosclerosis.2007.06.033
    1. Welsh P, Murray HM, Ford I, Trompet S, de Craen AJ, Jukema JW, Stott DJ, McInnes IB, Packard CJ, Westendorp RG, et al. Circulating interleukin‐10 and risk of cardiovascular events: a prospective study in the elderly at risk. Arterioscler Thromb Vasc Biol. 2011;31:2338–2344. doi: 10.1161/ATVBAHA.111.231795
    1. Fourman LT, Saylor CF, Cheru L, Fitch K, Looby S, Keller K, Robinson JA, Hoffmann U, Lu MT, Burdo T, et al. Anti‐inflammatory interleukin 10 inversely relates to coronary atherosclerosis in persons with human immunodeficiency virus. J Infect Dis. 2020;221:510–515. doi: 10.1093/infdis/jiz254
    1. Desvarieux M, Boccara F, Meynard JL, Bastard JP, Mallat Z, Charbit B, Demmer RT, Haddour N, Fellahi S, Tedgui A, et al. Infection duration and inflammatory imbalance are associated with atherosclerotic risk in HIV‐infected never‐smokers independent of antiretroviral therapy. AIDS. 2013;27:2603–2614. doi: 10.1097/QAD.0b013e3283634819
    1. Barbaro G. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr HIV Res. 2006;4:79–85. doi: 10.2174/157016206775197664
    1. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, Maa JF, Hodder S. Coronary heart disease in HIV‐infected individuals. J Acquir Immune Defic Syndr. 2003;33:506–512. doi: 10.1097/00126334-200308010-00012
    1. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case‐control study using Québec's public health insurance database. J Acquir Immune Defic Syndr. 2011;57:245–253. doi: 10.1097/QAI.0b013e31821d33a5
    1. Klein D, Hurley LB, Quesenberry CP, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV‐1 infection? J Acquir Immune Defic Syndr. 2002;30:471–477. doi: 10.1097/00126334-200208150-00002
    1. Lang S, Mary‐Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Bingham A, Costagliola D, French Hospital Database on HIV‐ANRS CO4 . Increased risk of myocardial infarction in HIV‐infected patients in France, relative to the general population. AIDS. 2010;24:1228–1230. doi: 10.1097/QAD.0b013e328339192f
    1. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sørensen HT, Gerstoft J. Ischemic heart disease in HIV‐infected and HIV‐uninfected individuals: a population‐based cohort study. Clin Infect Dis. 2007;44:1625–1631. doi: 10.1086/518285
    1. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–2512. doi: 10.1210/jc.2006-2190

Source: PubMed

3
Suscribir